GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advan...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

WBT614 Nov. 15 at 12:48 AM

$GTBP price has risen 6 of last 10 days so no surprise people took profit. Will rise again. Has good ratings. Yearly chart moving upward.

1 · Reply

WBT614 Nov. 15 at 12:00 AM

$GTBP has more than one employee. https://www.gtbiopharma.com/about/management-team

0 · Reply

Zackpedia Nov. 14 at 10:57 PM

$GTBP You could’ve sold today above 1.06 resistance, down to .65 now

1 · Reply

BearishAlgo Nov. 14 at 10:27 PM

Friday November 14th Recap: 1 Resistance Zone (Short Setup) Win Rate: 100.00% Total P&L: +11.91% $GTBP +11.91%✅ First Half: Covered at 6.67% Second Half: Covered at 17.14%

0 · Reply

Ridentuff Nov. 14 at 9:59 PM

$GTBP judging by your posts all we have to do is follow you and we’ll know which stocks to stay away from…

0 · Reply

Prs1234 Nov. 14 at 9:57 PM

$GTBP what are they doing for last 60 years . Company established in 1965.Only one employee .

1 · Reply

PAS_Trader Nov. 14 at 9:56 PM

$GTBP Graph shows dilution.. good luck. Every dollar will go to the CEO for Christmas.. scammm. Bye

0 · Reply

Jaspalding21 Nov. 14 at 9:54 PM

$GTBP you can make good money shorting every stock that pro ticker recommends. they may pop for a moments but they always tank after that

0 · Reply

PAS_Trader Nov. 14 at 9:53 PM

$GTBP 🤣🤣🤣🤣🤣

0 · Reply

PAS_Trader Nov. 14 at 9:51 PM

$GTBP 🤣🤣🤣🤣🤣🤣🤣🤣.

0 · Reply

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:05 PM EDT - 3 months ago

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 7:00 AM EDT - 3 months ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 13, 2025, 9:00 AM EDT - 5 months ago

GT Biopharma Appoints New Member to its Board of Directors

May 19, 2025, 9:00 AM EDT - 6 months ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Feb 25, 2025, 2:00 PM EST - 9 months ago

GT Biopharma Announces Exercise of Warrants

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Jun 27, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

May 21, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 1 year ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 26, 2024, 5:00 PM EDT - 1 year ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 1, 2024, 11:00 AM EST - 1 year ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Aug 7, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 1:25 PM EDT - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 4, 2023, 9:05 AM EDT - 2 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

Mar 30, 2023, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 9:00 AM EST - 2 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 3 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 11, 2022, 9:35 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Jun 10, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

May 16, 2022, 8:01 AM EDT - 3 years ago

GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

May 12, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference

Apr 11, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Mar 28, 2022, 4:15 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Mar 21, 2022, 7:30 AM EDT - 3 years ago

GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting

Mar 9, 2022, 4:24 PM EST - 4 years ago

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

Mar 3, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

Feb 24, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences

Feb 18, 2022, 7:30 AM EST - 4 years ago

GT Biopharma Appoints Manu Ohri as Chief Financial Officer

Jan 20, 2022, 7:30 AM EST - 4 years ago

GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference

WBT614 Nov. 15 at 12:48 AM

$GTBP price has risen 6 of last 10 days so no surprise people took profit. Will rise again. Has good ratings. Yearly chart moving upward.

1 · Reply

WBT614 Nov. 15 at 12:00 AM

$GTBP has more than one employee. https://www.gtbiopharma.com/about/management-team

0 · Reply

Zackpedia Nov. 14 at 10:57 PM

$GTBP You could’ve sold today above 1.06 resistance, down to .65 now

1 · Reply

BearishAlgo Nov. 14 at 10:27 PM

Friday November 14th Recap: 1 Resistance Zone (Short Setup) Win Rate: 100.00% Total P&L: +11.91% $GTBP +11.91%✅ First Half: Covered at 6.67% Second Half: Covered at 17.14%

0 · Reply

Ridentuff Nov. 14 at 9:59 PM

$GTBP judging by your posts all we have to do is follow you and we’ll know which stocks to stay away from…

0 · Reply

Prs1234 Nov. 14 at 9:57 PM

$GTBP what are they doing for last 60 years . Company established in 1965.Only one employee .

1 · Reply

PAS_Trader Nov. 14 at 9:56 PM

$GTBP Graph shows dilution.. good luck. Every dollar will go to the CEO for Christmas.. scammm. Bye

0 · Reply

Jaspalding21 Nov. 14 at 9:54 PM

$GTBP you can make good money shorting every stock that pro ticker recommends. they may pop for a moments but they always tank after that

0 · Reply

PAS_Trader Nov. 14 at 9:53 PM

$GTBP 🤣🤣🤣🤣🤣

0 · Reply

PAS_Trader Nov. 14 at 9:51 PM

$GTBP 🤣🤣🤣🤣🤣🤣🤣🤣.

0 · Reply

stockusfrance Nov. 14 at 9:47 PM

$GTBP Wanted to buy it. Thats why it's dropping.

0 · Reply

Ridentuff Nov. 14 at 9:43 PM

$GTBP holding 28k at .76

1 · Reply

WolfpackOfOne Nov. 14 at 9:40 PM

$GTBP sold at .96. Back in at .66.

0 · Reply

PAS_Trader Nov. 14 at 9:38 PM

$GTBP criminals…

0 · Reply

Manjunk Nov. 14 at 9:37 PM

$GTBP wow PRO TICKER P&D 🖕🏿 Them

0 · Reply

SmallCapAnalysis Nov. 14 at 9:36 PM

$GTBP And this Sir is trading

0 · Reply

jshade00722 Nov. 14 at 9:26 PM

$GTBP 1 employee. Michael Martin Breen. What a bunch of bs. Thanks for the momentum trade assholes. This is why people commit suicide. No morals in the stock market whatsoever.

1 · Reply

cfvk Nov. 14 at 9:21 PM

$GTBP added some .66ah.

0 · Reply

RunnerSignals Nov. 14 at 9:21 PM

$CDTX $CYCU $IVVD $TOI $GTBP lighting up the tape today. Wild swings and bigger stories behind the charts. Curious what sparked the chaos? https://stocksrunner.com/news/2025-11-14-movers-and-shakers-leading-today-market-buzz

0 · Reply

Ggnutty Nov. 14 at 9:20 PM

$GTBP give up glta sold for massive

0 · Reply

Dr_Monkeybreath Nov. 14 at 9:20 PM

$GTBP 5,300 @ .78. this thing is crazy. leaving it alone til Monday.

0 · Reply

kaaaam Nov. 14 at 9:19 PM

$GTBP $GTBP pro ticker = scam ticker how many got scammed 😂🤣🤣

1 · Reply

Market Cap	2.60M
Revenue (ttm)	0.00
Net Income (ttm)	-13.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	13,185,500
Avg Vol	2,358,806
Day's Range	N/A - N/A
Shares Out	3.56M
Stochastic %K	62%
Beta	1.38
Analysts	Sell
Price Target	$11.00